GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
TUESDAY, Sept. 30, 2025 -- Patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have better long-term outcomes compared with those taking other diabetes or weight-loss medications, according to a study presented at the European Academy of Dermatology and Venereology Congress 2025, held from Sept. 17 to 20 in Paris.
Henning Olbrich, from the University of Lübeck in Germany, and colleagues conducted a retrospective population-based cohort study using real-world data from the global TriNetX database to identify patients with psoriasis who were treated for diabetes or obesity with GLP-1 RAs. Over two years, cardiovascular, inflammatory, and psychiatric outcomes were compared for individuals treated with GLP-1 RAs and those treated with other systemic antidiabetic or obesity drugs. The analysis included 3,048 propensity-matched participants (1:1) in each cohort.
The researchers found that GLP-1 RA treatment was associated with significantly decreased all-cause mortality (hazard ratio [HR], 0.219) and a reduced risk for major adverse cardiac events (HR, 0.561). Additionally, GLP-1 RA-treated individuals had lower risks for alcohol (HR, 0.346) and substance abuse (HR, 0.510). The GLP-1 RA cohort did not experience more frequent typical adverse drug events. Risk reductions were even stronger in those with psoriasis versus persons with obesity or type 2 diabetes without psoriasis.
"Psoriasis management has traditionally focused on controlling skin symptoms, but these findings emphasize the need to consider the wider health risks faced by patients," lead author Ralf Ludwig, M.D., Ph.D., also from University of Lübeck, said in a statement. "GLP-1 RAs may offer a valuable dual benefit, improving both metabolic control and long-term health outcomes, representing an important step forward in holistic care for people living with psoriasis."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Diabetes Tied to Doubled Risk for Sepsis
FRIDAY, Sept. 26, 2025 -- People living with type 2 diabetes experience double the risk for incident sepsis versus matched individuals without diabetes, according to a study...
Clinical Practice Guidelines Issued for Diabetes Distress
THURSDAY, Sept. 25, 2025 -- The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the...
Oral Orforglipron Yields Greater Weight Reductions Than Placebo
THURSDAY, Sept. 25, 2025 -- For adults with obesity who do not have diabetes, the oral glucagon-like peptide-1 receptor agonist orforglipron yields significantly greater...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.